Autologous cytokine‐induced killer (<scp>CIK</scp>) cells enhance the clinical response to <scp>PD‐1</scp> blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study
Ying Han(Fujian University of Traditional Chinese Medicine), Xiubao Ren(Tianjin Medical University Cancer Institute and Hospital), Huan Zhang(First Affiliated Hospital of Chongqing Medical University), Ting Liu(Chinese PLA General Hospital), Rui Wang(Sun Yat-sen University), Xinwei Zhang(Southeast University), Jiali Zhang(Wuhan University), Shuzhan Li(Tianjin Medical University Cancer Institute and Hospital), Weijiao Du(Tianjin Medical University Cancer Institute and Hospital), Di Mu(Tianjin Medical University Cancer Institute and Hospital), Zhenzhen Hui(Tianjin Medical University Cancer Institute and Hospital)
Cited by 24
Related Papers
The Proteomics Identifications (PRIDE) database and associated tools: status in 2013
|Nucleic Acids Research|2012|2k
Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis
|Cancer Cell|2008|917
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth
|JAMA|2015|420
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
|Journal of Thoracic Oncology|2021|311